Labiotech.eu’s Post

Pretty interesting innovative announcement from Roche Diagnostics, which has received approval for a new way to diagnose Polycystic Ovary Syndrome (PCOS) PCOS. PCOS is a common condition in women that can affect their reproductive system, metabolism, and mental well-being. The new method involves a blood test called Elecsys Anti-Müllerian Hormone (AMH) which is a huge development because it provides a quicker, easier way to diagnose PCOS for women with less discomfort. Previous methods, like transvaginal ultrasounds, can be uncomfortable. This is significantly different than the in vitro diagnostic test offered by Roche which is helping to change the landscape to provide further equity and access for the women's health landscape. https://lnkd.in/dNawPKbM

The diagnosis of an underlying cause of pelvic pain in women takes years. #endometriosis is one of the most common causes, but yet we have a lot to learn about the molecular pathways involved in endometriosis in order to develop or improve new and existing therapies, especially with respect to pain. Calling all the investigators concentrating on #chronicpelvicpain and #endometriosis to submit their research on #endometriosis to this special issue: https://lnkd.in/dmQeqRB4 #pelvicpainmanagement #endometriosis #endometriosistreatment #gosiagenomics #womenhealth #womenpelvichealth

In 2023, several research findings related to endometriosis have emerged. Some of the latest advancements include: 1. A study published in Science Translational Medicine found that endometriosis may be caused by a bacterial infection. This discovery could potentially lead to new treatments and a better understanding of the condition. 2. A global study revealed compelling evidence of a shared genetic basis for endometriosis and other types of pain seemingly unrelated to endometriosis. This finding could help researchers develop more targeted treatments for endometriosis. 3. A potential new treatment for endometriosis is being tested in a groundbreaking clinical trial involving 100 women in Edinburgh and London. The trial aims to assess whether the drug dichloroacetate helps relieve pain, which could be the first non-hormonal, non-surgical treatment for endometriosis. 4. Research has shown that pelvic floor therapy could be key to tackling endometriosis-induced pain. A 2021 study showed that incorporating pelvic floor therapy as part of a lifestyle could help women with deeply infiltrative endometriosis (DIE) – a type of endometriosis that can invade the pelvic cavity. These findings contribute to the ongoing research and development of new treatments and interventions for managing endometriosis, a condition that affects around 190 million women and girls globally. #EndometriosisAwareness #EndoWarrior #EndoStrong #EndoCommunity #EndoSupport #EndoSisters #EndoAdvocate #EndoLife #EndoAware #EndoFighter #EndoPain #EndoAwarenessMonth #EndoResearch #EndoHealth #EndoAwarenessCampaign

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/eue8-d_M Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

Time to Prioritize Endometriosis! That’s the call from three leading researchers (Linda Giudice, Andrew Horne, and Stacey Missmer) and they’re right. It’s about time to make some progress.   Published in Nature Communications, they outline the scope of the problem, highlight the pain afflicting tens of millions of women, and call for policy and research to focus on addressing this unmet need. (https://lnkd.in/edzDeYxs)   We would add a fourth bullet point under the call on their graphic, that “millions of lives would be improved with”:       => A safe and effective non-hormonal drug; suitable for long-term use   SLBST Pharma is working hard to make this goal a reality in the next few years!   #endometriosis #nonhormonal #womenshealth #SLBSTPharma

Ophthopedia Update:The impact of achieving target intraocular pressure on glaucomatous retinal nerve fiber layer thinning in a treated clinical population: Estimate the effect of being below and above the clinician-set target intraocular pressure (IOP) on rates of glaucomatous retinal nerve fiber layer (RNFL) thinning in a treated real-world clinical population. #Ophthalmology #Ophthotwitter #Scicomm

Exciting research on R399E potential for osteoarthritis treatment! Learn how it could restore joints and relieve pain. (https://lnkd.in/eHy2n_df) https://lnkd.in/eVwmmeMr #Osteoarthritis #Jointpain #GDF5 #animalwelfare Kerstin Kleinschmidt-Doerr Christian Brenneis Stephanie Herzog Hans Guehring Frances Henson MA VetMB PhD CertES Cert EM DipECVSMR Christian Thudium Kyra Cowan Djordje Musil Merck Healthcare

Decoding Digital Therapeutics (DTx) Innovations: Strategic Insights for New DTx Products Development An in-depth search, review, and analysis of global patents related to DTx as of Q4 2023 can provide valuable insights into the state-of-the-art DTx innovations and related developments of new DTx products for various health conditions. The elaboration on insights into the development of new DTx products, based on transformative advancements in DTx innovations, showcases the burgeoning field of DTx as a beacon of hope and innovation in healthcare. This narrative underscores the potent synergy between cutting-edge technologies and deep scientific insights, heralding a new era in the personalized, efficient, and accessible management of various health conditions. The exploration of insights into the development of new DTx products paints a promising picture of the future of healthcare. Invitation to Review: Jacqueline Lutz, PhD, Matt Golden, Dawn Wiggins, MSc, RPN, CDP, Thierry Gricourt, Joris Van Dam, Bruce Imbert MD, PhD, MPH, Andy Molnar, Tony J Simon, Ph.D., Marguerite Manteau-Rao, LCSW, MBA, Emanuela Kufel, Laura Taraboanta, Klaudia Grzeszczak - Dobrev, Lisa Britton, MBA, Robin Ingle, Daa Un Moon, Austin Peck, PhD, James Faux, Wes Hassan, Mehrdad Seirafi, Abby (Captain) Doctolero, Freddy Nguyen, MD, PhD, Mainul Mondal, Erki Mölder, Patrick Candela, Grzegorz Bulaj, Lindsay Ayearst, PhD, Bikram Gangwar, Evans D. Pope, III, Rebecca Jackson, Bryan Wempen, Christopher Kommatas, Renata Redondo Bonaldi, PhD, Global MBA, Jacqueline Summers, Joseph Perekupka, Juliesta E. Sylvester, Ph.D., Peter Lee, Peter Ball, Kalyan Kalwa, Ricardo Sáinz Fuertes LMS MSc MRCPsych PhD, Przemek Grzywa #healthcare #digitalhealth #digitaltherapeutics #ai #artificialintelligence #virtualreality #innovation #productiveenvironment #patents #alzheimers #mentalhealth #autism #adhd #cancer

The pace of trial recruitment for Alzheimer's disease is lagging behind scientific advancements, particularly in early-phase clinical trials. Parexel experts Lydia Morris and Jakki James emphasize the significance of listening to and engaging with the concerns of prospective trial participants. They also propose innovative solutions for earlier diagnoses and the identification of surrogates for patients. Read the latest blog from our neurosciences trial series here: https://lnkd.in/gD7qVKMh Message me if you would like to learn more about how Parexel is increasing efficiencies in clinical trial participation! #Alzheimers #EarlyPhase #ClinicalResearch #PatientsFirst

Important document to share with the relevant authorities in your country to advocate for Newborn Screening for Duchenne